Boehringer Ingelheim Expands Facility in Greece for Production of New Therapeutics

Published on: 

Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.

On Jan. 11, 2024, Boehringer Ingelheim announced that it is investing €120 million (US$131 million) to further expand and upgrade its production facility in Koropi, Greece. With the investment, the company plans to increase manufacturing capacity of new and existing medications, some of which are in late-stage development in the company’s pipeline. The company is investigating several main disease areas, including cardio-renal-metabolic diseases, mental health, and pulmonary fibrosis.

According to a company press release, the expansion will boost medicine exports from Greece, in particular Jardiance (empagliflozin) for treating type 2 diabetes, chronic (long-term) heart failure, and chronic kidney disease, to the US market. The expansion will also create 110 additional jobs. The company had originally announced multi-year investments in 2020 to expand the Koropi site and its production capacity.

The expansion falls in line with the company’s goal of implementing innovative production technologies to support its R&D activities, the company stated in its press release. In 2022, the company spent €4.6 billion (US$5 billion) for its Human Pharma R&D unit, with 25% of Human Pharma net sales being reinvested to advance science and cutting-edge research for innovative therapeutics.


“This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally,” said Hubertus von Baumbach, chairman of the board of managing directors at Boehringer Ingelheim, in the press release.

Source: Boehringer Ingelheim